UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 19, 2011

TRANZYME, INC.

(Exact name of registrant as specified in its charter)

DELAWARE		001-35119		63-1192270
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

4819 Emperor Boulevard, Suite 400

Durham, NC

27703

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code (919) 313-4760

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 19, 2011, Brenda D. Gavin, D.V.M. tendered her resignation from the Board of Directors (the “Board”) of Tranzyme, Inc. (the “Company”) and all committees of the Board. Dr. Gavin will continue to serve as a director until her replacement is identified and duly elected to the Board. Dr. Gavin’s resignation was not the result of any disagreements with the Company on any matter relating to the Company’s operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 20, 2011	Tranzyme, Inc.

	By:	/s/ Vipin K. Garg
		Vipin K. Garg, Ph.D.
		President and Chief Executive Officer